content_image/224549.jpg
The movement of other intangible assets for the year ended 31 March 2014 is as follows: 

<img src='content_image/224549.jpg'>

(Note) “Other” mainly includes exchange differences. 

Amortisation of other intangible assets related to the rights of product or research and development arising from in-licensing agreements is recognised in the consolidated statements of income under “Amortisation of intangible assets”. 

Impairment losses for other intangible assets are recognised in the consolidated statements of income under “Other expense”. 

## Impairment test and impairment losses for other intangible assets 

For the intangible assets other than goodwill, the Group assesses the necessity of impairment by individual asset. Also, intangible assets not yet being amortised are tested for impair- ment annually whether or not there is any indication of impair- ment. For the impairment test, the value in use, which is calculated based on the five-year cash-flow forecast, is used as the recoverable amount. The discount rate is calculated based on the WACC, and the range of post-tax discount rate used for the calculation of the value in use is 6.0% to13.0%, and that of pre-tax discount rate is 9.3% to 21.5%. 

As a result of the impairment test, the Group recognised the following impairment losses for the years ended 31 March 2013 and 2014. 

For the year ended 31 March 2013, impairment losses recognised for other intangible assets were ¥42,673 million, and the details of the main items are as follows: 

(i) Impairment losses of ¥33,059 million were mainly recog- nised due to the discontinuation of development activities for IPR&Ds. This includes the discontinuation of develop- ment of OSI-027 (renal cell cancer), PSN821 (Type 2 diabetes, obesity), hepatocellular carcinoma line of erlotinib (Tarceva), and also one resulting from the exercise of the right to terminate the license agreement with Ambit about Quizartinib (Acute myeloid leukemia) and others. 

(ii) Impairment losses of ¥9,424 million were mainly recog- nised due to revising sales projections downwards for certain marketed products as the profitability was lower than originally expected. These losses are related mainly to the Qutenza cutaneous patch for the treatment of peripheral neuropathic pain marketed in Europe and Regnite for the treatment of restless legs syndrome marketed in Japan. 

